Conakry

THE LANCET by Kate Zinszer and others.                   Aug. 24,2015

In a speed outpacing control efforts, the Ebola virus disease (EVD) epidemic in parts of west Africa spread across Guinea, Liberia, and Sierra Leone infecting an estimated 26 800 individuals and claiming more than 11 000 lives as of May 15, 2015.¹ Mobile populations coupled with porous borders^{1, 2} and commercial air travel patterns³ affected the frequency and breadth of Ebola virus transmission.

MEDGADGET                                                                                   Aug. 20, 2015

BOSTON --At the 250^th National Meeting & Exposition of the American Chemical Society this week, researchers from MIT, Harvard Med School, and the FDA are showing off a new field test that can quickly screen people for Ebola, yellow fever, and dengue. While the researchers don’t claim their technique to be as accurate as PCR and ELISA, it is nevertheless an excellent tool in poor areas of the world where these diseases tend to thrive.

The test doesn’t require any water or electricity nor any complicated and expensive equipment. It works similar to pregnancy tests, providing a color readout that signals whether a disease is detected that is easily readable by just about anyone.

SCIENCE    by  Katie  M. Palmer                      Aug. 15, 2015

For the communities in Guinea, Sierra Leone, and Liberia where Ebola took the greatest toll last year, the worst is over. After claiming 11,000 lives, the fatal virus has finally begun to retreat. Numbers of new Ebola cases are dwindling. But for some of the survivors—the 50 percent or so of the infected who pull through—Ebola’s effects still linger.

                            Ebola survivor Fayiah, 11, sits with her relatives in Monrovia, Liberia. Jerome Delay/AP

For the communities in Guinea, Sierra Leone, and Liberia where Ebola took the greatest toll last year, the worst is over. After claiming 11,000 lives, the fatal virus has finally begun to retreat. Numbers of new Ebola cases are dwindling. But for some of the survivors—the 50 percent or so of the infected who pull through—Ebola’s effects still linger.

HUFFINGTON POST  by Mandeep Dhaliwal, Director of UNDP’s HIV, Health and Development Group, Bureau of Policy and Programme Support      Aug. 10, 2015                                                                 

While scientists still need to figure out how long the protective effect of the vaccine lasts, and how effective it will be among the general population and with different strains of the virus, without a doubt this is an important tool for the protection of health and community workers and possibly the wider community. This will certainly help in the on-going efforts to achieve the target of zero new Ebola cases and in overall recovery efforts.